Firas Warda, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1568993715
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 68.5% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $24,981, more than ten times the $245 reported in 2021. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 567 payments — averaging $66.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$26K
- Medtronic$1K
- Insulet Corporation$1K
- Corcept Therapeutics$1K
- Novo Nordisk$948
- Abbott$892
- plus $6K from 31 others
Across 8 payments — averaging $51,768 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$414K
What the payments were for
- Speaking & faculty fees$22,33559%
- Travel & lodging$1,9285%
- Food & beverage$13,54436%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 92 | $25,918 |
| Medtronic | 48 | $1,419 |
| Insulet Corporation | 85 | $1,377 |
| Corcept Therapeutics | 33 | $1,316 |
| Novo Nordisk | 62 | $948 |
| Abbott | 44 | $892 |
| Xeris Pharmaceuticals, Inc. | 20 | $853 |
| Lilly USA, LLC | 35 | $747 |
| Mannkind Corporation | 5 | $599 |
| Bayer | 23 | $581 |
| Dexcom, Inc. | 14 | $464 |
| Recordati_rare_diseases_inc. | 5 | $368 |
| Boehringer Ingelheim | 15 | $341 |
| Ascendis Pharma Endocrinology Inc | 12 | $294 |
| Sanofi-aventis U.S. LLC | 12 | $271 |
| AbbVie | 16 | $228 |
| BETA Bionics, Inc. | 2 | $175 |
| Tandem Diabetes Care, Inc. | 3 | $155 |
| Amryt Pharma Holdings Ltd | 3 | $132 |
| Radius Health, Inc. | 4 | $100 |
| AstraZeneca | 4 | $86 |
| IBSA Pharma Inc. | 4 | $71 |
| Amneal Pharmaceuticals LLC | 4 | $60 |
| Neurocrine Biosciences, Inc. | 2 | $59 |
| Antares Pharma, Inc. | 3 | $58 |
| Ascensia Diabetes Care US Inc. | 3 | $52 |
| Ionis Pharmaceuticals, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $36 |
| Chiesi USA, Inc. | 1 | $34 |
| Sequel Med Tech, LLC | 1 | $31 |
| Lifescan, Inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $27 |
| Boston Scientific | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Cequr Corporation | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$9,272
- AFREZZA$557
- Korlym$481
- iLet Bionic Pancreas$443
- RECORLEV$443
- MINIMED 780G$403
- SIGNIFOR LAR$292
- ISTURISA$292
- Kerendia$280
- EVENITY$242
- iLet Insulin Infusion Kit Inset$148
- iLet Insulin Infusion Kit Contact Detach$148
- RYBELSUS$135
- Ozempic$135
- FREESTYLE LIBRE 3$126
- Repatha$125
- Omnipod$118
- DEXCOM G6 TRANSMITTER$101
How this compares
$37,856 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 467 | $651,648 |
| JardianceEmpagliflozin | 331 | $437,982 |
| TrulicityDulaglutide | 166 | $226,844 |
| JanuviaSitagliptin Phosphate | 185 | $225,981 |
| MounjaroTirzepatide | 92 | $152,410 |
| FarxigaDapagliflozin Propanediol | 89 | $98,410 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 79 | $87,117 |
| KerendiaFinerenone | 48 | $73,070 |
| ProliaDenosumab | 28 | $49,514 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $45,233 |
| RybelsusSemaglutide | 19 | $41,962 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $41,265 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $37,234 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $36,960 |
| TradjentaLinagliptin | 25 | $33,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $948 | $711,730524 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $341 | $491,845371 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humalog | $747 | $403,174298 claims |
| MerckJanuvia, Janumet Xr | $14 | $234,901199 claims |
| AstraZenecaFarxiga | $86 | $98,41089 claims |
| BayerKerendia | $581 | $73,07048 claims |
| AmgenProlia | $25,918 | $49,51428 claims |
| AbbVieSynthroid | $228 | $12,003130 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $60 | $3,462445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Wasim DeebJacksonville$286K
- Khurram WadudJacksonville$77K
- Senan SultanJacksonville$55K
- Maria Hurtado AndradeJacksonville$36K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.